secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-265702
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Larimar Therapeutics Q3 2025: Net loss $47.7M, nomlabofusp shows 100% FXN level in OL study
--------------------------------------------------------------------------------

- Net loss for Q3 2025 was $47.7M ($0.61 per share) vs $15.5M in Q3 2024, with R&D expenses up to $44.9M.
- 100% of participants (n=10) achieved skin FXN levels similar to asymptomatic carriers after 6 months of daily nomlabofusp in open-label study.
- Anaphylaxis occurred in 7 of 65 total participants; new modified starting dose regimen implemented to mitigate risk, agreed with FDA.
- BLA submission seeking accelerated approval targeted for Q2 2026, with $175.4M cash runway into Q4 2026.
- Consistent directional improvement across mFARS, FARS-ADL, 9-HPT, and MFIS after 1 year versus worsening in FACOMS reference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000119312525265702/0001193125-25-265702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000119312525265702/lrmr-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-265702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer